primary outcome
Last imported at : June 30, 2022, 4:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
1. Antibody titers against Spike protein after interchangeability of the study vaccines at baseline; 28 days of first and second dose; 6 months and 1 year. <br/ >2. Incidence of mild; moderate and serious adverse events rate of the Covid-19 vaccines after interchangeability <br/ >3. Breakthrough infection rate of the Covid-19 vaccines (Covishield/Covaxin/Sputnik V) after interchangeability.Timepoint: At at baseline; 28 days of first and second dose; 6 months and 1 year.
|
Arms
Last imported at : June 30, 2022, 4:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
[{"arm_notes": "", "treatment_id": 1522, "treatment_name": "Chadox1 ncov-19+gam-covid-vac", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2546, "treatment_name": "Covaxin+gam-covid-vac", "treatment_type": "Inactivated virus+non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 1387, "treatment_name": "Covaxin", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 532, "treatment_name": "Gam-covid-vac", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 1898, "treatment_name": "Chadox1 ncov-19+covaxin", "treatment_type": "Non replicating viral vector+inactivated virus", "pharmacological_treatment": "Vaccine"}]
|